Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
300
mi
from 43215
Frederick, MD
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
300
mi
from 43215
Frederick, MD
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
902
mi
from 43215
Mesquite, TX
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
902
mi
from 43215
Mesquite, TX
Click here to add this to my saved trials
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated:  5/13/2014
Keesler Medical Center
738
mi
from 43215
Keesler AFB, MS
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated: 5/13/2014
Keesler Medical Center
738
mi
from 43215
Keesler AFB, MS
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
300
mi
from 43215
Frederick, MD
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
300
mi
from 43215
Frederick, MD
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
1069
mi
from 43215
Austin, TX
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from 43215
DeLand, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from 43215
DeLand, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
767
mi
from 43215
Edgewater, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
767
mi
from 43215
Edgewater, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from 43215
Miami Lakes, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from 43215
Miami Lakes, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
993
mi
from 43215
Miami, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
203
mi
from 43215
Granger, IN
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
203
mi
from 43215
Granger, IN
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
31
mi
from 43215
Cinicinnati, OH
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
31
mi
from 43215
Cinicinnati, OH
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
907
mi
from 43215
Carrollton, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
907
mi
from 43215
Carrollton, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
980
mi
from 43215
Channelview, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
980
mi
from 43215
Channelview, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
991
mi
from 43215
Houston, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
902
mi
from 43215
Mesquite, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
902
mi
from 43215
Mesquite, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
896
mi
from 43215
Plano, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
896
mi
from 43215
Plano, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated:  7/29/2014
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated: 7/29/2014
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated:  8/4/2014
University of California
2109
mi
from 43215
San Francisco, CA
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated: 8/4/2014
University of California
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1650
mi
from 43215
Mesa, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1650
mi
from 43215
Mesa, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
666
mi
from 43215
Hot Springs, AR
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
666
mi
from 43215
Hot Springs, AR
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1952
mi
from 43215
Covina, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1952
mi
from 43215
Covina, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2100
mi
from 43215
Palo Alto, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1939
mi
from 43215
Upland, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1939
mi
from 43215
Upland, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
539
mi
from 43215
Hamden, CT
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
539
mi
from 43215
Hamden, CT
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
429
mi
from 43215
Lewes, DE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
429
mi
from 43215
Lewes, DE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
772
mi
from 43215
Debary, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
772
mi
from 43215
Debary, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
916
mi
from 43215
Jupiter, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
916
mi
from 43215
Jupiter, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1508
mi
from 43215
Idaho Falls, ID
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1508
mi
from 43215
Idaho Falls, ID
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
404
mi
from 43215
Moline, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
404
mi
from 43215
Moline, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
353
mi
from 43215
Springfield, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
353
mi
from 43215
Springfield, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
471
mi
from 43215
Cedar Rapids, IA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
174
mi
from 43215
St. Clair Shores, MI
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
174
mi
from 43215
St. Clair Shores, MI
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
395
mi
from 43215
St. Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
395
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
721
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
462
mi
from 43215
Freehold, NJ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
462
mi
from 43215
Freehold, NJ
Click here to add this to my saved trials